Valuation: Satellos Bioscience Inc.

Market Cap 183M 160M 147M 136M 256M 17.6B 262M 1.76B 693M 8.62B 686M 671M 29.67B P/E 2026 *
-4.98x
P/E 2027 * -5.32x
Enterprise Value 89.09M 77.85M 71.84M 66.22M 125M 8.58B 128M 859M 338M 4.2B 335M 327M 14.46B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.52%
Yield 2026 *
-
Yield 2027 * -
1 day+1.07%
1 week-9.16%
Current month+15.29%
1 month+51.17%
3 months+3.19%
6 months+11.32%
Current year+55.18%
1 week 11.73
Extreme 11.73
13.74
1 month 7.76
Extreme 7.76
14.15
Current year 7.67
Extreme 7.67
18.98
1 year 6.36
Extreme 6.36
18.98
3 years 3.48
Extreme 3.48
18.98
5 years 2.58
Extreme 2.58
22.8
10 years 2.58
Extreme 2.58
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Chairman 59 01/07/2018
Director/Board Member 50 01/03/2018
Director/Board Member 70 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
18/6/26 Buy

Director

15,000 0.0720%
7/4/26 Buy

Director

4,500 0.0291%
7/4/26 Buy

Director

5,500 0.0356%
Change 5-day change 1-year change 3-year change Capi.($)
+1.07%-9.16%+73.59%+132.77% 183M
+0.24%-1.54%+52.85%+71.85% 53.83B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.39%-3.28%+43.85%+178.92% 23.37B
Weighted average by Cap. -2.80%-2.36%+39.57%+143.12%

Financials

2026 *2027 *
Net sales - -
Net income -48.32M -42.23M -38.97M -35.92M -67.7M -4.65B -69.2M -466M -183M -2.28B -181M -177M -7.85B -56.57M -49.43M -45.62M -42.05M -79.25M -5.45B -81.01M -545M -214M -2.67B -212M -208M -9.18B
Net Debt -93.65M -81.84M -75.52M -69.61M -131M -9.02B -134M -903M -355M -4.42B -352M -344M -15.21B -111M -97.31M -89.79M -82.77M -156M -10.72B -159M -1.07B -422M -5.25B -418M -409M -18.08B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
17/07/26 CAD 12.29 +1.07% 35,122
16/07/26 CAD 12.16 +0.16% 83,678
15/07/26 CAD 12.14 -4.48% 32,140
14/07/26 CAD 12.71 -1.09% 4,112
13/07/26 CAD 12.85 -5.03% 38,461
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.29CAD
Average target price
17.67CAD
Spread / Average Target
+43.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock